Medicare Enrolled
Dr. Fariborz Mortazavi, M.D.
Hematology & Oncology · Oxnard, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mortazavi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mortazavi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mortazavi
Dr. Fariborz Mortazavi is a hematology & oncology specialist in Oxnard, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mortazavi performed 9,389 Medicare services across 2,551 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mortazavi received a total of $12,368 from 77 pharmaceutical and/or device companies across 577 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mortazavi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 29% volume in CA
$12,368 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,389
Medicare services
Top 29% in CA for hematology & oncology
2,551
Unique beneficiaries
$41
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~494 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
3,080 | $8 | $18 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
2,839 | $8 | $30 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,120 | $102 | $195 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
627 | $72 | $150 |
| Enhanced Oncology Model monthly payment This code represents the monthly enhanced oncology services payment under the Enhancing Oncology Model. It covers the administrative payment for enhanced services provided to eligible patients. |
285 | $77 | $100 |
| New patient office visit, complex (60-74 min) | 196 | $173 | $375 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
99 | $98 | $205 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
44 | $140 | $395 |
| Prothrombin time test (blood clotting) A laboratory test that measures how long it takes for blood to clot. This procedure evaluates the body's coagulation process. |
41 | $4 | $25 |
| Biopsy of bone marrow | 23 | $138 | $425 |
| Bone marrow aspiration A procedure to remove a small sample of liquid bone marrow for diagnostic testing. |
22 | $70 | $375 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
13 | $153 | $250 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$12,368
Total received (2018-2024)
Avg $1,767/year across 7 years
Top 29% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
77
Companies
577
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,275 (99.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$94 (0.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,366
2023
$3,427
2022
$2,206
2021
$201
2020
$362
2019
$1,739
2018
$1,066
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$340
EMD Serono, Inc.
$320
ABBVIE INC.
$300
Novartis Pharmaceuticals Corporation
$279
Merck Sharp & Dohme LLC
$199
Astellas Pharma US Inc
$197
Incyte Corporation
$190
Celgene Corporation
$123
GlaxoSmithKline, LLC.
$118
Daiichi Sankyo Inc.
$104
Alexion Pharmaceuticals, Inc.
$101
AstraZeneca Pharmaceuticals LP
$87
Janssen Biotech, Inc.
$78
Gilead Sciences, Inc.
$72
Karyopharm Therapeutics Inc.
$65
Agios Pharmaceuticals, Inc.
$55
E.R. Squibb & Sons, L.L.C.
$55
GENZYME CORPORATION
$45
Fresenius Kabi USA, LLC
$44
Stemline Therapeutics Inc.
$43
Blueprint Medicines Corporation
$41
SOBI, INC
$41
Regeneron Healthcare Solutions, Inc.
$36
Genmab U.S., Inc.
$33
Takeda Pharmaceuticals U.S.A., Inc.
$31
Genentech USA, Inc.
$30
ARRAY BIOPHARMA INC
$30
Apellis Pharmaceuticals, Inc.
$30
SUN PHARMACEUTICAL INDUSTRIES INC.
$30
TAIHO ONCOLOGY, INC.
$29
Adaptive Biotechnologies Corporation
$26
Acrotech Biopharma Inc.
$25
Alnylam Pharmaceuticals Inc.
$21
Immunocore Limited
$21
Lilly USA, LLC
$21
Eisai Inc.
$21
Deciphera Pharmaceuticals Inc.
$21
Chiesi USA, Inc.
$17
Cumberland Pharmaceuticals, Inc.
$16
Coherus Biosciences Inc.
$15
ACCORD HEALTHCARE, INC.
$14
Top 3 companies account for 28.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$764
Incyte Corporation
$740
E.R. Squibb & Sons, L.L.C.
$663
PFIZER INC.
$649
Amgen Inc.
$575
ABBVIE INC.
$533
Celgene Corporation
$517
EMD Serono, Inc.
$486
AstraZeneca Pharmaceuticals LP
$478
Merck Sharp & Dohme LLC
$459
Janssen Biotech, Inc.
$412
Genentech USA, Inc.
$404
Pharmacyclics LLC, An AbbVie Company
$373
GlaxoSmithKline, LLC.
$352
Astellas Pharma US Inc
$331
Gilead Sciences, Inc.
$268
Blueprint Medicines Corporation
$245
Daiichi Sankyo Inc.
$221
Seagen Inc.
$207
Pharmacyclics LLC, an AbbVie Company
$193
Aurobindo Pharma USA, Inc.
$188
Karyopharm Therapeutics Inc.
$188
Merck Sharp & Dohme Corporation
$176
Alexion Pharmaceuticals, Inc.
$168
PharmaEssentia USA Corporation
$162
GE HealthCare
$145
GENZYME CORPORATION
$141
ADC Therapeutics America, Inc.
$137
Regeneron Healthcare Solutions, Inc.
$135
Exelixis Inc.
$134
Agios Pharmaceuticals, Inc.
$133
Spectrum Pharmaceuticals Inc.
$129
Seattle Genetics, Inc.
$124
Eisai Inc.
$109
TAIHO ONCOLOGY, INC.
$79
Foundation Medicine, Inc.
$76
Array BioPharma Inc.
$72
Ipsen Biopharmaceuticals, Inc
$71
EISAI INC.
$66
Genmab U.S., Inc.
$65
MorphoSys, US Inc.
$58
SOBI, INC
$53
Puma Biotechnology, Inc.
$52
Apellis Pharmaceuticals, Inc.
$50
Takeda Pharmaceuticals U.S.A., Inc.
$46
Fresenius Kabi USA, LLC
$44
Stemline Therapeutics Inc.
$43
ARRAY BIOPHARMA INC
$30
PORTOLA PHARMACEUTICALS, INC.
$30
SUN PHARMACEUTICAL INDUSTRIES INC.
$30
Coherus Biosciences Inc.
$30
Tactile Systems Technology Inc
$29
Mylan Institutional Inc.
$27
BeiGene USA, Inc.
$27
Sun Pharmaceutical Industries Inc.
$26
Adaptive Biotechnologies Corporation
$26
Acrotech Biopharma Inc.
$25
Clovis Oncology, Inc.
$24
Dendreon Pharmaceuticals LLC
$24
Kite Pharma, Inc.
$24
Myriad Genetic Laboratories, Inc.
$22
Janssen Pharmaceuticals, Inc
$22
Alnylam Pharmaceuticals Inc.
$21
Immunocore Limited
$21
Lilly USA, LLC
$21
Deciphera Pharmaceuticals Inc.
$21
Octapharma USA, Inc.
$20
Tolmar, Inc.
$18
AbbVie, Inc.
$17
Mirati Therapeutics, Inc.
$17
Chiesi USA, Inc.
$17
AMAG Pharmaceuticals, Inc.
$16
Cumberland Pharmaceuticals, Inc.
$16
Helsinn Therapeutics (U.S.), Inc.
$15
AVEO Pharmaceuticals, Inc.
$15
ACCORD HEALTHCARE, INC.
$14
NxStage Medical, Inc.
$11
Top 3 companies account for 17.5% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ANDEXXA · AYVAKIT · Abraxane · Avastin · BELEODAQ · BESREMI · BOSULIF · BRUKINSA · Bavencio · Blincyto · Braftovi · CABOMETYX · CALQUENCE · CAMCEVI · CUTAQUIG · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELREXFIO · ELZONRIS · ENHERTU · EPKINLY · ERLEADA · EVENITY · Empaveli · Enhertu · Epkinly · Erleada · FERAHEME · FERRIPROX · FOTIVDA · FOUNDATIONONE · FULPHILA · Fabhalta · Flexitouch Plus · Folotyn · GAVRETO · GAZYVA · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · NERLYNX · NINLARO · Neulasta · Nplate · OJJAARA · ONPATTRO · OPDIVO · OPDUALAG · Onivyde · Orserdu · PADCEV · PEMAZYRE · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Phesgo · Polivy · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SANCUSO · SARCLISA · SCEMBLIX · SOMATULINE DEPOT · SPRYCEL · Stimufend · System One · TAGRISSO · TALZENNA · TASIGNA · TECENTRIQ · TEPMETKO · TIBSOVO · TIVDAK · TUKYSA · Tecentriq · Trodelvy · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · Venclexta · XALKORI · XPOVIO · XTANDI · Xospata · Xtandi · YONSA · ZEJULA · Zevalin · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
19
Per 100K population
2.3
County median income
$107,327
Nearest hospital
ST JOHNS REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mortazavi is a clinical cardiology specialist, with above-average Medicare volume (top 29% in CA), with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mortazavi experienced with blood draw (venipuncture)?
Based on Medicare claims data, Dr. Mortazavi performed 3,080 blood draw (venipuncture) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mortazavi receive payments from pharmaceutical companies?
Yes. Dr. Mortazavi received a total of $12,368 from 77 companies across 577 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mortazavi's costs compare to other hematology & oncology specialists in Oxnard?
Dr. Mortazavi's average Medicare payment per service is $41. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mortazavi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Oxnard
Browse hematology & oncology specialists in Oxnard ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology